2790413-59-9
Chemical Structure
Ancelvotide Guraxetan
Synonym(s): PNT2001; LY4181530; PSMA-62
- CAS. Nr.: 2790413-59-9
- Formula:C85H107N15O32
- Molecular Weight:1850.84
InChIKey: YPKWNBDTFXWSLZ-CHJDRSDMSA-N
SMILES: OC(C=C1)=CC=C1C[C@@H](NC([C@@H](NC(CC[C@@H](N2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)=O)CC3=CC=C(C=C3)N)=O)C(N[C@@H](C(N[C@@H](C(O)=O)CCCCNC([C@@H](CC(NCCC[C@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)NC(C4=CC(C(O)=O)=CC(C(O)=O)=C4)=O)=O)=O)CC5=CC6=C(C=CC=C6)C=C5)=O
Biological Activity: PNT2001 (LY4181530) is a high-affinity PSMA-targeted radiopharmaceutical ligand precursor. natLu-PNT2001 has an IC50 of 3.1 nM against PSMA. PNT2001 is applicable for PSMA targeting, radiopharmaceutical ligand delivery, and prostate cancer-related research[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ancelvotide Guraxetan | 98.72% | PNT2001 (LY4181530) is a high-affinity PSMA-targeted radiopharmaceutical ligand precursor. natLu-PNT2001 has an IC50 of 3.1 nM against PSMA. PNT2001 is applicable for PSMA targeting, radiopharmaceutical ligand delivery, and prostate cancer-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vito A, et al. Development and characterization of 225Ac-PNT2001, a next-generation PSMA radioligand. EANM E-Poster. 2022.
- [2]. Saleh R, et al. ACCEL: [225Ac]-PSMA-62 Phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer. TPS282 Trials in Progress Poster Session. 2026.
